Mallinckrodt Inc

Mallinckrodt — Q3 2025 Earnings Presentation

17 slides from Mallinckrodt's earnings presentation, Nov 10, 2025

  1. Slide 1: 3Q25 Financial and Corporate Update

    3Q25 Financial and Corporate Update November 10, 2025

  2. Slide 2: Forward-Looking Statements and Additional Information

    Forward-Looking Statements and Additional Information Statements in this presentation that are not strictly historical, including statements regarding future financial condition and operating results of the combined business and Par Health, expected product launches, legal, economic, business, compe

  3. Slide 3: Non-GAAP Financial Measures

    Non-GAAP Financial Measures To supplement the financial measures prepared in accordance with U.S. generally accepted accounting principles (“GAAP”), this presentation includes certain financial information of the Companies that are not prescribed by or prepared in accordance with GAAP. We utilize th

  4. Slide 4: Agenda

    Agenda Keenova Overview 3Q25 Results 2025 Financial Guidance Appendix © 2025 KEENOVA THERAPEUTICS PLC OR ONE OF ITS AFFILIATES. ALL RIGHTS RESERVED. 4

  5. Slide 5: Transaction Structure & Timeline

    Transaction Structure & Timeline Transaction Developments: March 13, 2025: Mallinckrodt & Endo announce merger agreement July 31, 2025: Merger completed Step 1 Nov 10, 2025: Separation of Par Health as an independent Combined Company private company Creation of two separate entities: 1 Keenova: A le

  6. Slide 6: Keenova Overview

    Keenova Overview Addressing a wide range of therapeutic areas of significant unmet need 37% Rheumatology Neurology 34% Additional $1,870M – $1,890M Ophthalmology Urology Therapeutics 2025E Pro Forma Net Sales Nephrology Orthopedics Neonatal respiratory 29% Pulmonology critical care © 2025 KEENOVA TH

  7. Slide 7: 3Q25 Pro Forma Financial Highlights

    3Q25 Pro Forma Financial Highlights1 Net Sales Adjusted EBITDA2 $ million $ million YoY%Δ YoY%Δ $268 $869 3% $845 $7 $143 $123 $435 $480 10% $129 -52% $52 -64% $410 $389 -5% $125 $77 -38% 3Q24 3Q25 3Q24 3Q25 Par Health Keenova Par Health Keenova Transaction Comp 1 To aid with year-over-year comparab

  8. Slide 8: Acthar Gel Performance

    Acthar Gel Performance Robust double-digit growth driven by demand growth and a broadening prescriber base Acthar Gel Net Sales $ million +44% ➢ 3Q25 net sales: $181 million (+44% Y/Y) ▪ Commercial investments driving category awareness $181 and expansion ▪ Broadening prescriber base $126 $122 $126

  9. Slide 9: XIAFLEX Performance

    XIAFLEX Performance Growth impacted by timing of shipments XIAFLEX Net Sales $ million ➢ 3Q25 net sales: $130 million (+2% Y/Y) +2% ▪ Volume impacted by unexpected shipment delays ▪ Offset by net price $130 $128 $113 $104 3Q22 3Q23 3Q24 3Q25 © 2025 KEENOVA THERAPEUTICS PLC OR ONE OF ITS AFFILIATES.

  10. Slide 10: Keenova: Pro Forma 2025 Financial Guidance

    Keenova: Pro Forma 2025 Financial Guidance 4Q25 Guidance FY2025 Guidance $ million Current [a] Current [a] Prior Net sales $485 - $505 $1,870 - $1,890 $1,850 - $1,870 [b] Adjusted EBITDA – Implied $650 - $660 [b] (-) Par Health Stand-Up Costs [c] $35 (-) Compensation Expenses [d] $135 Adjusted EBITD

  11. Slide 11: Q&A

    Q&A © 2025 KEENOVA THERAPEUTICS PLC OR ONE OF ITS AFFILIATES. ALL RIGHTS RESERVED. 11

  12. Slide 12: Appendix

    Appendix © 2025 KEENOVA THERAPEUTICS PLC OR ONE OF ITS AFFILIATES. ALL RIGHTS RESERVED. 12

  13. Slide 13: Keenova Therapeutics

    Keenova Therapeutics1 Non-GAAP pro forma combined select product line net sales As Reported Pro Forma Non-GAAP Pro As Reported Pro Forma Non-GAAP Pro Adjustments2 Forma Combined Adjustments3 Forma Combined Unaudited, $ in millions Three Months Ended September 26, 2025 Three Months Ended September 27

  14. Slide 14: Par Health, Inc.

    Par Health, Inc.1 Non-GAAP pro forma combined select product line net sales As Reported Pro Forma Non-GAAP Pro As Reported Pro Forma Non-GAAP Pro Adjustments2 Forma Combined Adjustments3 Forma Combined Unaudited, $ in millions Three Months Ended September 26, 2025 Three Months Ended September 27, 20

  15. Slide 15: Keenova Therapeutics: Non-GAAP pro forma adjusted EBITDA

    Keenova Therapeutics Non-GAAP pro forma combined adjusted EBITDA Pro Forma Non-GAAP Pro Pro Forma Non-GAAP Pro As Reported Adjustments1 Forma As Reported Adjustments2 Forma Combined Combined Unaudited, $ in millions Three Months Ended September 26, 2025 Three Months Ended September 27, 2024 Segment

  16. Slide 16: Par Health, Inc.: Non-GAAP pro forma adjusted EBITDA

    Par Health, Inc. Non-GAAP pro forma combined adjusted EBITDA Non-GAAP Pro As Reported Pro Forma Forma As Reported Pro Forma Non-GAAP Pro Adjustments1 Combined Adjustments2 Forma Combined Unaudited, $ in millions Three Months Ended September 26, 2025 Three Months Ended September 27, 2024 GAAP Histori

  17. Slide 17: Non-GAAP Definitions

    Non-GAAP Definitions Legacy Mallinckrodt Adjusted EBITDA Pro Forma Combined Net Revenues Adjusted EBITDA represents net income or loss prepared in accordance with accounting Keenova Pro forma combined net revenues represent net revenues as if Mallinckrodt’s principles generally accepted in the U.S.

Mallinckrodt — Q3 2025 Earnings Presentation on 6ix